Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKinsey
Baxter
Merck
Dow

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Acalabrutinib - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for acalabrutinib and what is the scope of patent protection?

Acalabrutinib is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Acalabrutinib has ninety-eight patent family members in forty countries.

One supplier is listed for this compound.

Summary for acalabrutinib
Recent Clinical Trials for acalabrutinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AstraZenecaPhase 2
University of MiamiPhase 2
University of WashingtonPhase 1/Phase 2

See all acalabrutinib clinical trials

Recent Litigation for acalabrutinib

Identify potential future generic entrants

District Court Litigation
Case NameDate
Acerta Pharma B v. v. Pharmacyclics LLC2018-04-18

See all acalabrutinib litigation

Pharmacology for acalabrutinib
Drug ClassKinase Inhibitor
Mechanism of ActionTyrosine Kinase Inhibitors
Synonyms for acalabrutinib
(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
1420477-60-6
4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
Acalabrutinib (ACP-196)
Acalabrutinib (JAN/USAN/INN)
Acalabrutinib [INN]
Acalabrutinib [USAN:INN]
Acalabrutinib(ACP196)
ACP 196
ACP-196
ACP-196;Acalabrutinib
AK546544
AKOS030526094
BDBM50175583
Benzamide, 4-(8-amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-
Calquence
Calquence (TN)
CHEMBL3707348
CS-5356
D10893
DB11703
DS-3326
EX-A881
Example 6 [US20140155385 A1]
GTPL8912
HY-17600
I42748ELQW
J-690166
KS-000006AD
KS-000006AT
NCGC00479074-01
s8116
SB19176
SC-41557
SCHEMBL14637368
UNII-I42748ELQW
WDENQIQQYWYTPO-IBGZPJMESA-N
ZINC208774715

US Patents and Regulatory Information for acalabrutinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca CALQUENCE acalabrutinib CAPSULE;ORAL 210259-001 Oct 31, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Astrazeneca CALQUENCE acalabrutinib CAPSULE;ORAL 210259-001 Oct 31, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Astrazeneca CALQUENCE acalabrutinib CAPSULE;ORAL 210259-001 Oct 31, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKesson
Boehringer Ingelheim
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.